Literature DB >> 20385637

Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.

Sebastian Schneeweiss1, Amanda R Patrick, Daniel H Solomon, Colin R Dormuth, Matt Miller, Jyotsna Mehta, Jennifer C Lee, Philip S Wang.   

Abstract

OBJECTIVE: The objective of this study was to assess the risk of suicide attempts and suicides after initiation of antidepressant medication use by children and adolescents, for individual agents.
METHODS: We conducted a 9-year cohort study by using population-wide data from British Columbia. We identified new users of antidepressants who were 10 to 18 years of age with a recorded diagnosis of depression. Study outcomes were hospitalization attributable to intentional self-harm and suicide death.
RESULTS: Of 20,906 children who initiated antidepressant therapy, 16,774 (80%) had no previous antidepressant use. During the first year of use, we observed 266 attempted and 3 completed suicides, which yielded an event rate of 27.04 suicidal acts per 1000 person-years (95% confidence interval [CI]: 23.9-30.5 suicidal acts per 1000 person-years). There were no meaningful differences in the rate ratios (RRs) comparing fluoxetine with citalopram (RR: 0.97 [95% CI: 0.54-1.76]), fluvoxamine (RR: 1.05 [95% CI: 0.46-2.43]), paroxetine (RR: 0.80 [95% CI: 0.47-1.37]), and sertraline (RR: 1.02 [95% CI: 0.56-1.84]). Tricyclic agents showed risks similar to those of selective serotonin reuptake inhibitors (RR: 0.92 [95% CI: 0.43-2.00]).
CONCLUSION: Our finding of equal event rates among antidepressant agents supports the decision of the Food and Drug Administration to include all antidepressants in the black box warning regarding potentially increased suicidality risk for children and adolescents beginning use of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385637      PMCID: PMC2884182          DOI: 10.1542/peds.2009-2317

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

1.  Rare outcomes, common treatments: analytic strategies using propensity scores.

Authors:  Leonard E Braitman; Paul R Rosenbaum
Journal:  Ann Intern Med       Date:  2002-10-15       Impact factor: 25.391

2.  Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.

Authors:  Carlos Martinez; Stephan Rietbrock; Lesley Wise; Deborah Ashby; Jonathan Chick; Jane Moseley; Stephen Evans; David Gunnell
Journal:  BMJ       Date:  2005-02-19

3.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

4.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Simulation study of confounder-selection strategies.

Authors:  G Maldonado; S Greenland
Journal:  Am J Epidemiol       Date:  1993-12-01       Impact factor: 4.897

7.  Confounding and misclassification.

Authors:  S Greenland; J M Robins
Journal:  Am J Epidemiol       Date:  1985-09       Impact factor: 4.897

8.  Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study.

Authors:  Robert J Valuck; Anne M Libby; Marion R Sills; Alexis A Giese; Richard R Allen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Hospitalization for suicide attempt and completed suicide: epidemiological features in a managed care population.

Authors:  C Iribarren; S Sidney; D R Jacobs; C Weisner
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2000-07       Impact factor: 4.328

10.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

View more
  22 in total

1.  Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded.

Authors:  Amanda R Patrick; Matthew Miller; Catherine W Barber; Philip S Wang; Claire F Canning; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10-03       Impact factor: 2.890

2.  Antidepressant agents and suicide death among US Department of Veterans Affairs patients in depression treatment.

Authors:  Marcia Valenstein; Hyungjin Myra Kim; Dara Ganoczy; Daniel Eisenberg; Paul N Pfeiffer; Karen Downing; Katherine Hoggatt; Mark Ilgen; Karen L Austin; Kara Zivin; Frederic C Blow; John F McCarthy
Journal:  J Clin Psychopharmacol       Date:  2012-06       Impact factor: 3.153

Review 3.  Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Authors:  Paul R. Albert; Brice Le François; Faranak Vahid-Ansari
Journal:  J Psychiatry Neurosci       Date:  2019-05-01       Impact factor: 6.186

4.  Analysis of pediatric clinical drug trials for neuropsychiatric conditions.

Authors:  Srinivas Murthy; Kenneth D Mandl; Florence Bourgeois
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

5.  Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples.

Authors:  Jeremy A Rassen; Robert J Glynn; M Alan Brookhart; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2011-05-20       Impact factor: 4.897

6.  Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.

Authors:  Bhaven C Kataria; Dimple S Mehta; Sunita B Chhaiya
Journal:  Indian Heart J       Date:  2012-12-27

7.  How complete are E-codes in commercial plan claims databases?

Authors:  Christine Y Lu; Christine Stewart; Ameena T Ahmed; Brian K Ahmedani; Karen Coleman; Laurel A Copeland; Enid M Hunkeler; Matthew D Lakoma; Jeanne M Madden; Robert B Penfold; Donna Rusinak; Fang Zhang; Stephen B Soumerai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02       Impact factor: 2.890

Review 8.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

9.  Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data.

Authors:  Cheng Ju; Richard Wyss; Jessica M Franklin; Sebastian Schneeweiss; Jenny Häggström; Mark J van der Laan
Journal:  Stat Methods Med Res       Date:  2017-12-11       Impact factor: 3.021

10.  Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats.

Authors:  Andrew E Arrant; Elizabeth Coburn; Jacob Jacobsen; Cynthia M Kuhn
Journal:  Neuropharmacology       Date:  2013-06-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.